Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-01
2006-08-01
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C530S311000
Reexamination Certificate
active
07084117
ABSTRACT:
The present invention relates to a method of treating vascular proliferation in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a type-1 somatostatin agonist to said patient.
REFERENCES:
patent: 5750499 (1998-05-01), Hoeger et al.
patent: 5912247 (1999-06-01), Jinbo et al.
patent: 6060275 (2000-05-01), Hacohen et al.
patent: 6903074 (2005-06-01), Morgan et al.
patent: 2002/0103526 (2002-08-01), Steinke
patent: 96/07398 (1996-03-01), None
patent: 99/049884 (1999-10-01), None
patent: 99/056769 (1999-11-01), None
patent: 99/065508 (1999-12-01), None
patent: 00/12111 (2000-03-01), None
patent: WO 00/10552 (2000-03-01), None
Albini et al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB Journal. 1999, vol. 13, pp. 647-655.
Antonian et al. Biotransformations Of The Anti-Angiogenic Compound SU5416. Drug Metabolism And Disposition. 2000, vol. 28, No. 12, pp. 1505-1512.
Vajkoczy et al. Inhibition of Tumor Growth, Angiogenesis . . . Neoplasia. Apr. 1999, vol. 1, No. 1, pp. 31-41.
Mccombe, M. et al., “Effect of a Long-acting Somatostatin Analogue (BIM23104) on Proliferative Diabetic Retinopathy: A Pilot Study,” Eye, 1991, 5(5):569-575.
Aavik, E. et al., “Elimination of Vascular Fibrointimal Hyperplasia by somatostatin receptor,” FASEB, 2002, 16(7):2002-2005.
Barrie, R. et al., “Inhibition of Angiogenisis by Somatostatin and Somatostatin-like Compounds is Structurally Dependent,” J. of Surgical Research, 1993, 4(55):446-450.
Patel, Y.C., “Somatostatin and its receptor family”, Frontiers in Neuroendocrinology, 1999, 20:157-198.
Lapinski, et al., “Development of a selective agonist at the somatostatin receptor subtype SSTR1”, J. Pharm. Exper. Therap., 1996, 276:1089-1094.
Bocci Guido
Culler Michael Dewitt
Danesi Romano
Deltacca Mario
Feeney Alan F.
Morrill Brian R.
Russel Jeffrey Edwin
Societe de Conseils de Recherches et d'Applications Scientifique
Yankwich & Associates
LandOfFree
Pharmaceutical compositions which inhibit vascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions which inhibit vascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions which inhibit vascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3690801